MAPT and Alzheimer disease: Clinical examinations, including MRI, SPECT, FDG-PET, and plasma measurements, showed results compatible with a diagnosis of AD, whereas the amyloid PET yielded mainly negative results and the results of both tau PET and genome sequencing were inconclusive.